Keywords: algeta, hails, results, alpharadin, trial, norwegian, cancer

Algeta hails results of Alpharadin trial

Article | 19 January 2009

Print This

Norwegian cancer therapeutics company Algeta has reported strong results from a Phase II trial evaluating Alpharadin (radium-223) as a new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in